A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone

A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years. Hematologically and cytogenetically, he attained a continuing complete remission, although at one point (9.5 years) at least, after attaining complete remission molecular analysis indicated the presence of minimal residual disease

Specificity of bcr-abl antisense oligonucleotides.

Contains fulltext : 21162___.PDF (publisher's version ) (Open Access

New type of t(14;18) in a non-Hodgkin's lymphoma provides insight in molecular events in early B-cell differentiation

Contains fulltext : 20725.PDF (publisher's version ) (Open Access)rights: (c)RU Radboud Universiteit Nijmegen, 199

Automatisering van de moleculaire diagnostiek met behulp van capillaire electroforese

Item does not contain fulltex

Bax mutations in cell lines derived from hematological malignancies

Contains fulltext : 21561___.PDF (publisher's version ) (Open Access

Automatisering van de moleculaire diagnostiek met behulp van capillaire electroforese

Item does not contain fulltex

New type of t(14;18) provides indight in molecular events in early B cell differentiation.

Item does not contain fulltex

Bias in nucleotide composition of antisense oligonucleotides

Item does not contain fulltex